BRAF mutation is an important molecular target in melanoma. The clinical utility of BRAF and MEK inhibitors (dabrafenib, vemurafenib, trametinib and cobimetinib) has been validated as either mono, or combination therapy. However, the toxicity and the limited duration of disease control are still a problem in clinical practice. In a randomized phase III trial (COLUMBUS), patients with BRAF V600E or BRAF V600K advanced, unresectable or metastatic melanoma were treated with combination therapy (the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib) or monotherapy (the BRAF inhibitor encorafenib or vemurafenib). The median progression-free survival was 14.9 months in the combination group, 9.6 months in the encorafenib group and 7.3 months in the vemurafenib group. The toxicity was tolerable in the combination group. These results demonstrated that the new combination therapy has potential as a new treatment option in patients with BRAF-mutant melanoma.
Dummer R, et al. Lancet Oncol. pii: S1470-2045(18)30142-6 (2018)